Clinical Trials
2 trialsNCT07557914 2026-06-03
Epalrestat Combined With HAIC, Donafenib and Tislelizumab as First-line Treatment for Patients With Unresectable HCC and Diabetes
First Hospital of China Medical University
Phase 2 Not yet recruiting
NCT03244358 2021-01-29
Evaluation of Epalrestat in Metastatic Triple-negative Breast Cancer
Sun Yat-sen University
Phase 2 Terminated